420 related articles for article (PubMed ID: 25874329)
1. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.
Chikhale R; Menghani S; Babu R; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
Eur J Med Chem; 2015; 96():30-46. PubMed ID: 25874329
[TBL] [Abstract][Full Text] [Related]
2. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
[TBL] [Abstract][Full Text] [Related]
3. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
[TBL] [Abstract][Full Text] [Related]
4. Microwave-assisted synthesis, molecular docking and antitubercular activity of 1,2,3,4-tetrahydropyrimidine-5-carbonitrile derivatives.
Mohan SB; Ravi Kumar BV; Dinda SC; Naik D; Prabu Seenivasan S; Kumar V; Rana DN; Brahmkshatriya PS
Bioorg Med Chem Lett; 2012 Dec; 22(24):7539-42. PubMed ID: 23122523
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
[TBL] [Abstract][Full Text] [Related]
6. Virtual Screening of Small Molecular Inhibitors against DprE1.
Zhang G; Guo S; Cui H; Qi J
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
[TBL] [Abstract][Full Text] [Related]
7. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
[TBL] [Abstract][Full Text] [Related]
9. Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.
Whitehurst BC; Young RJ; Burley GA; Cacho M; Torres P; Vela-Gonzalez Del Peral L
Bioorg Med Chem Lett; 2020 Jun; 30(12):127192. PubMed ID: 32312582
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers.
Chikhale R; Thorat S; Pant A; Jadhav A; Thatipamula KC; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
Bioorg Med Chem; 2015 Oct; 23(20):6689-713. PubMed ID: 26385444
[TBL] [Abstract][Full Text] [Related]
11. Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains.
Liu J; Dai H; Wang B; Liu H; Tian Z; Zhang Y
Eur J Med Chem; 2022 Jan; 227():113932. PubMed ID: 34700267
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
[TBL] [Abstract][Full Text] [Related]
13. DprE1--from the discovery to the promising tuberculosis drug target.
Mikusová K; Makarov V; Neres J
Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
[TBL] [Abstract][Full Text] [Related]
14. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
[TBL] [Abstract][Full Text] [Related]
15.
Borthwick JA; Alemparte C; Wall I; Whitehurst BC; Argyrou A; Burley G; de Dios-Anton P; Guijarro L; Monteiro MC; Ortega F; Suckling CJ; Pichel JC; Cacho M; Young RJ
J Med Chem; 2020 Mar; 63(5):2557-2576. PubMed ID: 31922409
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis of benzocoumarin-pyrimidine hybrids as novel class of antitubercular agents, their DNA cleavage and X-ray studies.
Reddy DS; Hosamani KM; Devarajegowda HC
Eur J Med Chem; 2015 Aug; 101():705-15. PubMed ID: 26210508
[TBL] [Abstract][Full Text] [Related]
17. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
18. Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme.
Karan S; Kashyap VK; Shafi S; Saxena AK
J Mol Model; 2017 Aug; 23(8):241. PubMed ID: 28744747
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents.
Aziz Ali A; Gogoi D; Chaliha AK; Buragohain AK; Trivedi P; Saikia PJ; Gehlot PS; Kumar A; Chaturvedi V; Sarma D
Bioorg Med Chem Lett; 2017 Aug; 27(16):3698-3703. PubMed ID: 28712709
[TBL] [Abstract][Full Text] [Related]
20. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the
Ezquerra-Aznárez JM; Degiacomi G; Gašparovič H; Stelitano G; Sammartino JC; Korduláková J; Governa P; Manetti F; Pasca MR; Chiarelli LR; Ramón-García S
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]